Where it comes from
- Made in
- Chromaffin cells of the adrenal medulla and sympathetic nerve endings, released with catecholamines
- Sent out by
- With adrenaline and noradrenaline, as a brake on their own release
- Acts on
- Chromaffin cells
- Sympathetic nerve terminals
- Heart
- Vessels (histamine release from mast cells)
What it does
- Shuts off catecholamine release, a negative feedback on the cells that made it 1
- Lowers blood pressure and slows the heart
- Kills bacteria and fungi in the laboratory
In medicine
- Catestatin is already low in the still-healthy children of people with hypertension, and the Gly364Ser variant changes autonomic function and lowers diastolic pressure by about 5 to 6 mmHg 2
- No approved test and no medicine. Chromogranin A, the protein it comes from, is measured as a neuroendocrine tumour marker, and that result says nothing about catestatin
- Measuring it is the hard part. It is one cut piece of a storage protein that is chopped into many fragments, and the antibodies in use differ in which fragments they see, so published concentrations differ by more than the diseases do 3
Beyond the body’s own use
- A fragment of a storage protein is not a hormone with a gene of its own. Chromogranin A packages catecholamines inside the granule, and catestatin is one of the pieces left when that package is processed, so how much exists is a question about processing rather than about CHGA expression 1
- It is studied as a marker in heart failure, where plasma concentrations predicted death or unplanned admission over two years in a 52-patient cohort; nothing of the kind is in clinical use 3
- It lowers blood pressure in hypertensive rats and kills microbes in a dish. No human trial has been registered, and the measurement problem above is why one would be hard to design 2
Sources
- Mahata et al., Novel autocrine feedback control of catecholamine release, Journal of Clinical Investigation 1997
- Rao et al., Catestatin variant Gly364Ser and human autonomic activity, Circulation 2007
- Wołowiec et al., Catestatin as a prognostic marker in heart failure with reduced ejection fraction, Disease Markers 2020
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.